Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Ophthalmology

Understanding Scleromalacia Perforans

At a Glance

Scleromalacia perforans is a rare form of scleritis that thins and weakens the white outer wall of the eye without typical redness or pain. Specialist eye monitoring and protection from injury are important, especially with long-standing rheumatoid arthritis.

Scleromalacia perforans is a rare and specific form of scleritis (inflammation of the white part of the eye). While most forms of scleritis cause intense, deep-seated pain and bright red eyes, scleromalacia perforans is unique because it is “quiet” [1]. It is defined as necrotizing anterior scleritis without inflammation [2]. This means the tissue of the eye wall (the sclera) begins to thin and break down without the usual warning signs of redness, heat, or pain [3][4].

Because it does not hurt, it can be startling to look in the mirror and see significant changes in the eye’s appearance. Understanding the mechanics behind these changes can help you work with your care team to protect your vision.

What This Does Not Mean: A blue-gray area on the white of the eye is not diagnostic by itself and does not mean your eyeball is literally dissolving. Visible changes should be assessed by an ophthalmologist rather than self-diagnosed from a mirror.

Why the Eye Changes Color and Shape

The “white” of your eye, the sclera, is a thick, opaque layer of tough fibers that holds the eye’s shape and protects the delicate structures inside. In scleromalacia perforans, these fibers undergo necrosis—a process where the tissue breaks down and thins [5].

As the sclera thins, two distinct changes occur:

  • The Bluish Tint: The sclera is normally thick enough to hide the layer underneath it called the uvea, which is filled with blood vessels and dark pigment [6]. As the sclera becomes transparent or paper-thin, the dark pigment of the uvea begins to show through, making the eye appear dark blue or gray [1][7].
  • The Bulging: The eye is filled with fluid that maintains a certain level of pressure. When the wall of the eye loses its structural strength, that internal pressure can cause the thinned area to bow outward [8]. This outward bulging is known as ectasia or a staphyloma [1][9].

A Rare Condition

If your local eye doctor seems surprised by your diagnosis, it is because scleromalacia perforans is exceptionally rare. Overall, scleritis affects only about 1.4 to 6.8 people out of every 100,000 each year [10][11]. Necrotizing forms represent only a small fraction of those cases in referral cohorts [12][13].

Scleromalacia perforans is most commonly seen in people who have had rheumatoid arthritis for a long time, often decades [2][14]. In these cases, the same immune system processes that affect the joints can affect the collagen fibers in the eye [15].

Understanding “Perforans”

The word “perforans” refers to the severe thinning that could lead to a tear or opening in the eye wall [7]. However, the goal of modern medical management is to stabilize the eye wall and prevent this from happening.

Because this condition is usually painless, your doctor will not be able to rely on your symptoms to know if it is getting worse. Instead, they will use specialized tools to monitor the eye:

  • Slit-lamp examination: A high-powered microscope used to look for thinning or loss of blood vessels in the sclera [8].
  • Anterior-segment OCT: A type of imaging that creates a detailed cross-section map of the eye wall to measure how thin it has become [16].
  • Systemic Testing: Blood work to check for markers of autoimmune activity, ensuring that your underlying condition is being managed alongside the eye symptoms [17][18].

While the physical changes to the eye’s appearance can be distressing, they are a signal that the eye needs protection. Because the eye wall is thinner than normal, it is more vulnerable to injury; your doctor may recommend wearing protective eyewear or eye shields to prevent accidental trauma [7].

Plain Language Glossary

  • Sclera: The tough, white outer layer of the eyeball.
  • Scleritis: Inflammation of the sclera.
  • Necrotizing: A medical term for tissue that is breaking down or dying.
  • Uvea: The dark, vascular layer of tissue just beneath the sclera.
  • Ectasia / Staphyloma: A bulging outward of the eye wall due to thinning.
  • Globe Perforation: A full-thickness hole or opening in the eye wall.
  • ANCA: A type of antibody blood test used to look for vasculitis.
  • Tectonic Graft: A surgical patch used to reinforce the structure of the eye.

Common questions in this guide

What is scleromalacia perforans?
Scleromalacia perforans is a rare form of scleritis in which the sclera, the white outer wall of the eye, becomes very thin and weak without the usual redness or severe pain. The thinning can let the darker layer beneath the sclera show through and can weaken the eye wall.
What causes the eye to look blue-gray or bulge in this condition?
When the sclera becomes paper-thin, the darker, blood-vessel-rich uvea beneath it can show through and create a blue-gray appearance. Loss of wall strength can also allow normal pressure inside the eye to push the thin area outward, a change called ectasia or staphyloma.
Can scleromalacia perforans get worse without pain?
Yes. This condition is often painless and may not cause the redness typical of other forms of scleritis, so symptoms alone may not show whether thinning is progressing. An ophthalmologist can use a slit-lamp examination and anterior-segment OCT imaging to check the eye wall.
Is scleromalacia perforans linked to rheumatoid arthritis?
It is most commonly seen in people who have had rheumatoid arthritis for a long time, sometimes for decades. Immune system activity involved in rheumatoid arthritis can affect collagen in the eye, but your doctors must assess your individual situation.
How do doctors check for scleromalacia perforans?
An ophthalmologist uses a slit lamp, a high-powered microscope, to look for scleral thinning and loss of blood vessels. Anterior-segment OCT maps the eye wall in cross-section, and blood tests may help assess autoimmune activity and the underlying condition.
How can I protect an eye affected by scleromalacia perforans?
A thinned eye wall is more vulnerable to accidental injury, so your ophthalmologist may recommend protective eyewear or an eye shield. Ask your care team what activities to avoid and which new changes require urgent evaluation, because the condition can progress without pain.
Does a blue-gray patch mean the eye has already perforated?
No. A blue-gray area can occur when the uvea shows through a thinned sclera, but color alone cannot diagnose scleromalacia perforans or a hole in the eye wall. An ophthalmologist needs to examine and image the eye to assess its strength and look for ectasia or other structural changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my current eye presentation match the clinical definition of scleromalacia perforans (necrotizing scleritis without inflammation)?
  2. 2.How thin is my sclera, and are there signs of ectasia or staphyloma (bulging)?
  3. 3.Since I don't have pain, how will we monitor for progression or changes in the structure of my eye?
  4. 4.Does this diagnosis change how we should be managing my underlying rheumatoid arthritis or other systemic conditions?
  5. 5.What specific signs should I look for that would indicate the 'quiet' thinning is becoming an emergency?
  6. 6.What are the risks of globe perforation in my specific case, and what protective measures (like eye shields) should I use?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Sclerokeratitis and Secondary Glaucoma in Relapsing Polychondritis in a 30-Year-Old Asian Male Patient: A Case Report.

    Flores LKC, Siazon RR

    Cureus 2025; (17(2)):e79128 doi:10.7759/cureus.79128.

    PMID: 40109806
  2. 2

    [Diagnostic and Therapeutic Management of Episcleritis and Scleritis].

    Turgut F, Dingerkus V, Tappeiner C, Becker M

    Klinische Monatsblatter fur Augenheilkunde 2023; (240(5)):725-738 doi:10.1055/a-2022-0689.

    PMID: 36827997
  3. 3

    [Diagnosis and treatment approach for necrotizing scleritis (NS): A clinical case].

    Hernández-Camarena JC, Rodríguez-García A, Valdez-García J

    Gaceta medica de Mexico 2015; (151(4)):525-8.

    PMID: 26290030
  4. 4

    [Scleritis and systemic diseases: What should know the internist?]

    Bielefeld P, Saadoun D, Héron E, et al.

    La Revue de medecine interne 2018; (39(9)):711-720 doi:10.1016/j.revmed.2018.02.001.

    PMID: 29496270
  5. 5

    Biodegradable collagen matrix (Ologen™) implant and conjunctival autograft for scleral necrosis after pterygium excision: two case reports.

    Cho CH, Lee SB

    BMC ophthalmology 2015; (15()):140 doi:10.1186/s12886-015-0130-z.

    PMID: 26499993
  6. 6

    Autologous Pericranium Graft for Necrotizing Scleritis.

    Copete S, Fagúndez-Vargas MA, López-Martínez F, et al.

    Cornea 2024; (43(12)):1567-1569 doi:10.1097/ICO.0000000000003643.

    PMID: 39079757
  7. 7

    Scleromalacia perforans: a case report.

    Ghauri MI, Riaz SU, Husain A, et al.

    Journal of medical case reports 2018; (12(1)):155 doi:10.1186/s13256-018-1686-z.

    PMID: 29866188
  8. 8

    Treatment of Progressive Scleromalacia Perforans by Tectonic Enhancement With Lyophilized Equine Pericardium.

    Droutsas K, Giachos I, Katsiampoula V, et al.

    Cornea 2021; (40(5)):648-651 doi:10.1097/ICO.0000000000002465.

    PMID: 32925429
  9. 9

    Spontaneous Descemet Membrane Detachment After Necrotizing Scleritis: A Case Report.

    Margulies KS, Kiavash V, Syed ZA

    Cornea 2026; (45(2)):239-242 doi:10.1097/ICO.0000000000003930.

    PMID: 40600595
  10. 10

    The Global Epidemiology of Scleritis: A Systematic Review and Meta-analysis.

    Cifuentes-González C, Mejía-Salgado G, Rojas-Carabali W, et al.

    American journal of ophthalmology 2025; (273()):13-32 doi:10.1016/j.ajo.2025.01.019.

    PMID: 39892801
  11. 11

    Incidence and Prevalence of Scleritis Subtypes and Associated Ocular Complications in the TriNetX Database.

    Spangler MD, Marshall RF, Kirupaharan N, et al.

    American journal of ophthalmology 2025; (277()):365-374 doi:10.1016/j.ajo.2025.05.028.

    PMID: 40447245
  12. 12

    Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS)-report 4: analysis and outcome of scleritis in an East Asian population.

    Bin Ismail MA, Lim RHF, Fang HM, et al.

    Journal of ophthalmic inflammation and infection 2017; (7(1)):6 doi:10.1186/s12348-017-0124-5.

    PMID: 28205148
  13. 13

    Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis).

    Yoshida A, Watanabe M, Okubo A, Kawashima H

    Japanese journal of ophthalmology 2019; (63(5)):417-424 doi:10.1007/s10384-019-00674-7.

    PMID: 31183624
  14. 14

    Case of isolated scleromalacia perforans with seropositivity for rheumatoid arthritis.

    Hajizadeh S, O'Donnell C, Dore A

    BMJ case reports 2024; (17(6)) doi:10.1136/bcr-2024-259863.

    PMID: 38925670
  15. 15

    Potential Biomarkers for Noninfectious Scleritis Identified by Serum and Tear Fluid Proteomics.

    Vergouwen DPC, Kolijn PM, de Hoog J, et al.

    Ophthalmology science 2024; (4(1)):100407 doi:10.1016/j.xops.2023.100407.

    PMID: 38054106
  16. 16

    Case Report: Subconjunctival Triamcinolone Acetate-associated Scleral Necrosis: Is It Really Obsolete?

    Agarwal R, Bafna RK, Chetan C, Sharma N

    Optometry and vision science : official publication of the American Academy of Optometry 2021; (98(9)):1016-1020 doi:10.1097/OPX.0000000000001761.

    PMID: 34433205
  17. 17

    Necrotizing Scleritis: A Review.

    Dutta Majumder P, Agarwal S, Shah M, et al.

    Ocular immunology and inflammation 2024; (32(7)):1405-1419 doi:10.1080/09273948.2023.2206898.

    PMID: 37279404
  18. 18

    ANCA-associated scleritis: impact of ANCA on presentation, response to therapy and outcome.

    Perray L, Nguyen Y, Clavel Refregiers G, et al.

    Rheumatology (Oxford, England) 2024; (63(2)):329-337 doi:10.1093/rheumatology/kead252.

    PMID: 37233203

This page explains scleromalacia perforans for informational purposes only and does not constitute medical advice. An ophthalmologist and the clinicians managing any underlying rheumatoid arthritis should interpret your findings and recommend monitoring or protection.

Get notified when new evidence is published on scleromalacia perforans.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.